Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbb-2, and cathepsin D protein

Journal of Surgical Oncology

Volumn 65, Issue 1, 1997, Pages 22-27

  Han, Sehwan ^a   Yun, Ik Jin ^b   Noh, Dong Young ^b   Choe, Kuk Jin ^b   Song, Sang Yong ^b   Chi, Je G ^b  

^a Inje University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

metastasis; prognosis; recurrence; survival

Indexed keywords

CATHEPSIN D; PROTEIN P53; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER SURGERY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; CATHEPSIN D; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NUCLEOSIDE-DIPHOSPHATE KINASE; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030952105     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199705)65:1<22::AID-JSO5>3.0.CO;2-Q     Document Type: Article

References (33)

1. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 4,740 breast cancer cases. Cancer 1989;63:181-187.
2. Fisher B, Slack NH: Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 1970;131: 79-88.
3. Allred DC, Bustamante MA, Daniel CO: Immunocytochemical analysis of estrogen receptors in human breast carcinomas: Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990;125:107-113.
4. Benner SE, Clark GM, McGuire WL: Review: Steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer. Am J Med Sci 1988;296:59-66.
5. Knight WA, Livingstone RB, Gregory EJ, McGuire WL: Estrogen receptors as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977;37:4669-4671.
6. Clark GM, McGuire WL, Hubay CA, et al.: Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 1983;309:1343-1347.
7. Fisher B, Redmond C, Fisher ER, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients. Findings from National Surgical Adjustment Breast and Bowel Project protocol B-06. J Clin Oncol 1988;6: 1076-1087.
8. Hopton DS, Thorogood J, Clayden AD, MacKinnon D: Observer variation in histologie grading of breast cancer. Eur J Surg Oncol 1989;15:21-23.
9. Wood WC: Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node-negative breast cancer patients. World J Surg 1994;18:39-44.
10. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 1992;70:523-526.
11. Davidoff AM, Kerns B-JM, Iglehart JD, Marks JR: Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991;51:2605-2610.
12. Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-1114.
13. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS: Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph-node involvement and other histopathological indicators of high metastatic potential. Cancer Res 1989; 49:5185-5190.
14. Steeg PS, Bevilacqua G, Kopper L, et al.: Evidence tor a novel gene associated with low tumor-metastatic potential. J Natl Cancer Inst 1988;80:200-204.
15. Sastre-Garau X, Lacombe ML, Jouve M, et al.: Nucleoside diphosphate kinase/nm23 expression in breast cancer: Lack of correlation with lymph-node metastasis. Int J Cancer 1992;50:533-538.
16. Callahan R, Campbell G: Mutations in human breast cancer: An overview. J Natl Cancer Inst 1989;81:1780-1786.
17. Borg A, Tandon AK, Sigurdsson H, et al.: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-4337.
18. Marks JR, Humphrey PA, Wu K, et al.: Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994;219:332-341.
19. Kobayashi S, Iwase H, Itoh Y, et al.: Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers. Jpn J Cancer Res 1992;83: 859-865.
20. McGuire WL, Tandon AK, Allred DC, et al.: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-1015.
21. Morisset M, Capony F, Rochefort H: The 52kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun 1986;138:102-109.
22. Mathieu M, Vignon F, Capony F, Rochefort H: Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: A receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol Endocrinol 1991;5:815-822.
23. Rochefort H, Capony F, Augereau P, et al.: The estrogen-regulated 52k-cathepsin-D in breast cancer: From biology to clinical applications. Nucl Med Biol 1987;14:377-384.
24. Rochefort H, Capony F, Garcia M: Cathepsin D in breast cancer: From molecular and cellular biology to clinical applications. Cancer Cells 1990;2:383-388.
25. Henry JA, McCarthy AL, Angus B, et al.: Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer 1990;65:265-271.
26. Isola J, Weitz S, Visakorpi T, et al.: Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 1993; 11:36-43.
27. Royds JA, Stephenson TJ, Rees RC, et al.: Nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 1993;85:727-731.
28. Harris AL: Cancer genes. Telling changes of base. Nature 1991; 350:377-378.
29. Chang F, Syrjanen S, Syrjanen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-1022.
30. Ostrowski JL, Sawan A, Henry L, et al.: p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study. J Pathol 1991;164:75-81.
31. Gullick WJ, Love SB, Wright C, et al.: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-438.
32. Gasparini G, Gullick WJ, Bevilacqua P, et al.: Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992;10:686-695.
33. Gusterson BA, Gelber RD, Goldhirsch A, et al.: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049-1056.